HealthCap Research
Investment Thesis
HealthCap is a European life science investor and company creator built around a narrow but durable thesis: back breakthrough therapies and related healthcare innovations where the unmet medical need is high enough to justify long development cycles, intensive diligence, and active ownership. The firm repeatedly describes its motivation as finding innovative ideas and investing in people and companies that can impact healthcare and society. That language is not generic branding. It is consistent across the homepage, strategy page, and ESG report, and it points to a firm that wants to be involved in science that can change clinical practice rather than fund incremental product updates.
The firm’s strategy emphasizes precision medicine-based pharmaceuticals, diseases with significant unmet need, and therapies that can be transformative for patients, payors, and healthcare systems. HealthCap also presents itself as a company creator, which suggests that it is comfortable not only financing businesses but also helping shape them. That matters in life sciences, where governance, regulatory execution, and scientific judgment can be as important as capital. The site explicitly says HealthCap team members sometimes take key operational roles in portfolio companies, which is a strong signal that the firm wants real influence, not passive exposure.
Stage Focus
HealthCap appears to invest across the early and middle stages of life science development, with a bias toward companies that are close enough to value inflection to support with governance and development expertise, but still early enough that the firm can help shape the outcome. The portfolio and news flow point to seed, Series A, and Series B activity, with some later-stage follow-on exposure in listed or near-listed assets.
The firm is not a broad generalist growth investor. Its portfolio includes clinical-stage biotech, public company holdings, and medical device businesses, but the common thread is therapeutic or healthcare product depth. That mix implies a stage preference that is less about fixed round labels and more about development stage, proof of mechanism, and ability to create clinical and commercial evidence.
Check Size
HealthCap does not publicly state a canonical check size on its site, so I am not treating any number as confirmed. The evidence supports a range of meaningful institutional checks rather than seed-sized experimental tickets. The firm has participated in large financings such as Hemab, Adcendo, and other clinical-stage companies, which implies the ability to write material follow-on capital when the science and governance case is strong.
Lead Tendency
HealthCap often behaves like a lead or anchor investor, or at minimum a highly engaged partner. The public site and news items repeatedly frame deals as being led by HealthCap, and the firm’s strategy stresses active involvement. Its willingness to take board or operational roles reinforces the idea that it prefers influence and stewardship over simply collecting exposure.
Recent Activity
HealthCap looks actively deployed in 2026. Recent public activity includes a led investment in Neobiomics on 20 May 2026 to support neonatal care expansion, plus a July 2026 homepage feature on Hemab presenting new clinical data at ISTH 2026. The firm also surfaced an intercompany governance update in February 2026 when Intervacc announced a CEO change, and it continues to publish and spotlight portfolio progress through its media archive.
Older but still important milestone activity includes the March 2024 sale of Fusion Pharmaceuticals to AstraZeneca for up to $2.4 billion. That exit is a strong proof point for HealthCap’s ability to back scientific platforms that can reach meaningful strategic outcomes. The firm’s portfolio and media pages also show continuing breadth across therapeutics, diagnostics, and animal health.
Portfolio Highlights
HealthCap’s portfolio spans both private and public life science names. Notable companies include:
- Adcendo
- Aro Biotherapeutics
- Hemab Therapeutics
- Fusion Pharmaceuticals
- Vicore Pharma
- Oncopeptides
- Intervacc
- Neobiomics
- Positrigo
- BONESUPPORT
- Aprea Therapeutics
- Altimmune
The mix says a lot about the firm: it is comfortable with deep biotech risk, translational medicine, and companies with long regulatory runways. The exit of Fusion and the scale of the Hemab and Adcendo financings suggest that HealthCap invests in platforms that can produce real clinical and strategic value, not just narrow one-off assets.
Team
HealthCap’s team page shows a large, medically fluent partnership structure. The first names that matter most for orientation are:
- Björn Odlander, Managing Partner
- Mårten Steen, Managing Partner
- Kristina Ekberg, Partner
- Carl Kilander, Partner
- Johan Christenson, Partner
- Staffan Lindstrand, Partner
- Per Samuelsson, Partner
- Max Odlander, Partner
- Alex Valcu, Partner
- Daniel Karsberg, Partner
The broader team also includes venture partners, associates, and operating support roles, which matters because HealthCap describes itself as more than a capital provider. The firm’s bench is built to support science, regulation, and governance across a long development cycle.
Decision Process
The decision process appears to be a partnership model rather than a solo-gp style motion. HealthCap’s public materials emphasize team expertise across medicine, pharmacology, engineering, law, and finance, and the strategy page repeatedly frames investment as a long-term, diligence-heavy process. That suggests a collaborative internal decision path with scientific and operational input, especially on companies with complex clinical or regulatory profiles.
Founder Preferences
HealthCap seems to prefer founders and teams who are scientifically serious, highly credentialed, and willing to work closely with the firm on development, financing, and governance. The firm values medical knowledge, breakthrough science, and the ability to translate research into products that matter to patients. It also appears to like teams that can handle regulatory complexity and benefit from a hands-on investor.
Geographic Focus
HealthCap is Europe-focused but explicitly global. The site says it invests globally in life sciences and also looks at North America. Its portfolio and offices show a Nordic core with broader reach into the US, Switzerland, Canada, and other markets. Stockholm is the clearest operational center, with Lausanne also listed on the site.